PHARMACY

Half of in-store sales digitally influenced

BY Antoinette Alexander

While online sales of allergy products may still be relatively low, thousands of consumers are making these purchases online — and many millions more are using the Web to learn about products and decide which brands to purchase.

That’s why it’s critical for brands to optimize four key areas — online search, images, content and availability, according to a new report from Clavis Insight. Search is the new shelf, the company noted, and the rules for winning online versus winning in store are vastly different.

Deloitte estimates that 50% of in-store sales are now digitally influenced, meaning that many allergy sufferers are turning to the Internet to research allergy products, brands and forms — even when making their purchases in physical stores, according to the Clavis Insight report.

However, simply having an online presence is not enough. Fewer than 30% of Amazon shoppers click beyond the first page of search results, according to Millward Brown Digital. So, if a brand is not returning on the first one or two pages of key search term results, it isn’t “on shelf” for those consumers. “Optimizing your products to rank in the top 20 against key category search terms, and then consistently monitoring search performance, is imperative for online success,” said Clavis Insight researchers.

So, who is winning? New entrants and private-label brands are taking the lead in terms of online presence. Flonase and Nasacort, nasal sprays previously available only by prescription, have worked their way to the top of the Allergy Clavis Insight Index ranking with consistent availability and top search results across retailers. Meanwhile, private label is giving brands a run for their money as retailer brands tend to perform better in search terms on retailer sites.

The analysis was conducted based on data collected from six U.S. online stores — Amazon.com, CVS.com, drugstore.com, Target.com, Walgreens.com and Walmart.com. The analysis includes 56 brands and 784 SKUs across the category.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Cannabis pharmacy premieres in U.K.

BY Antoinette Alexander

LONDON — Carun Pharmacy, the United Kingdom’s first cannabis pharmacy, officially opened its doors in May in Twickenham, London, offering consumers a range of health and beauty products that harness the healing powers of hemp.

Carun product offerings include Virgin Hemp Oil, which, according to the company, has a large range of health benefits and is the ideal replacement for traditional cooking oils; Hemp bio syrup, which is suitable for adults and children with respiratory problems, cough and cold; and Hemp Seed, which promotes a healthy metabolism when taken as part of a healthy balanced diet.

“I feel incredibly excited to be opening the first cannabis pharmacy in the United Kingdom. Carun products are made from a specially cultivated species of cannabis sativa called Carmagnola. The compounds called Cannabinoids, which act on Cannabinoid receptors on our cells surface, are very similar to those which [the] human body naturally produce in our Endocanabinoid system,” explained Michal Takac, Carun’s U.K. managing director. “These support our immune system, restore the balance and health of cells, as well as possess anti-inflammatory, antiseptic and antibiotic properties. But no … they will not and cannot make you high.” Unlike marijuana, which has a THC level of 20% to 30% (the psychoactive chemical that creates a “high”), Carun products only contain around 0.3%. With anti-inflammatory, antibacterial and hypoallergenic properties, the Carun line soothes and heals such skin conditions as rashes, allergies, psoriasis, eczema, wrinkles, stretch marks, bedsores, scars, burns, sunburn, and dry, cracked or sensitive skin, the company stated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Vote against trade bill continues debate over generic access

BY Michael Johnsen

WASHINGTON — The U.S. House of Representatives on Friday rejected the first of a series of trade bills, placing the Trans-Pacific Partnership trade agreement in jeapordy and ensuring a continued debate between branded and generic pharmaceutical manufacturers over the trade pact’s possible impact on the availability of generic drugs. 
 
“In today’s debate on the Trade Promotion Authority, members of the U.S. House of Representatives rightly expressed strong reservations about the Trans-Pacific Partnership,” Ralph Neas, president and CEO of the Generic Pharmaceutical Association, said on Friday. “As it stands now, TPP will make it harder for the U.S. generic industry to sell its products overseas. That is because the intellectual property provisions in TPP are designed to give longer protection to patented drugs and postpone the entry of cost-saving generic medicines. The U.S. generic industry cannot support a TPP that benefits only one side of the pharmaceutical industry, jeopardizing the right of patients in America and around the world to have timely access to affordable medicines.”
 
The New York Times recently reported that the Obama administration is no longer demanding protection for pharmaceutical prices under the trade agreement, which critics suggest will empower pharmaceutical manufacturers to command higher reimbursement rates. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?